TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients~* Patients who met DSM-IV criteria for major depressive disorder(MDD):a single major depressive episode or recurrent major depressive episode, without psychotic features, MDD is primary mental disorder~* Age from 18-65 years old, male or female~* HAMD-17 total score at least 20 at screening and baseline, and first item's score at least 2~* CGI-S at least 4 at screening and baseline~* Written informed consent provided by patient himself/herself~Exclusion Criteria:~* Severe suicide attempt~* Any unstable medical illness would affect study or increase patients' risk to participate this study, including disease of heart, lung, liver, kidney,cardiovascular system, eyes, nervous system, endocrine system, hematological system etc.~* History of epilepsy(except children febrile seizure/convulsion)~* Known history of high intraocular pressure or angle closure glaucoma~* Psychoactive substance abuse or dependence within 1 year prior enrollment~* Depressive episode due to other mental disorders or physical diseases~* Bipolar disorder, rapid cycling/circulation~* Female patients during their pregnant and lactation period or childbearing potential during study~* History of severe drug hypersensitivity~* A significantly clinical abnormal value in ECG or lab results which would affect assessment for efficacy or safety decided by the investigator~* ALT and AST values in the liver function test exceeding two times of the upper limits of normal values~* Participation in another drug trial within 28 days prior enrollment into this study~* Use of MAOI within 4 weeks prior to randomization~* Duration of discontinuing other psychotropics is shorter than its 7 half life periods~* Patients can not administrate drug according to medical order~* HAMD total score decreased more than 25% from screening to baseline~* Use of Electroconvulsive therapy within half year prior enrollment~* Known lack of efficacy to escitalpram by formal treatment before~* Other situation unsuitable to enroll in this study as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Generic Escitalopram Oxalate Tablets
- 2 (Type: ACTIVE_COMPARATOR): Innovator Escitalopram(Lexapro®)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infants born at ≤1,000 g birth weight~* Infant is ≤8 0/7 weeks of age at the time of eligibility assessment~* Pediatric surgeon decision to perform surgery for suspected NEC or IP~* Subject is at a center able to perform both laparotomy and drainage~Exclusion Criteria:~* Major anomaly that influences likelihood of developing primary outcome or affects surgical treatment considerations~* Congenital infection~* Prior laparotomy or peritoneal drain placement~* Prior NEC or IP~* Infant for whom full support is not being provided~* Follow-up unlikely

- Gender: ALL
- Minimum Age: None
- Maximum Age: 8 Weeks
- Healthy Volunteers: f

Study Arms:
- Randomized Trial: Laparotomy (Type: ACTIVE_COMPARATOR): Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
- Randomized Trial: Peritoneal drain placement (Type: ACTIVE_COMPARATOR): Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
- Preference Cohort: Laparotomy (Type: ACTIVE_COMPARATOR): Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
- Preference Cohort: Peritoneal drain placement (Type: ACTIVE_COMPARATOR): Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture in Chronic Migraine: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 75 years old~* Patients were required to have a diagnosis of chronic migraine with or without medication overuse that satisfied the ICHD-2 criteria during the last 3 months prior to trial entry, with an established migraine history for at least 1 year.~Exclusion Criteria:~* Patients did not fulfill the criteria of ≧ 15 days or response to triptans or ergots on at least 8 days in prospective baseline periods .~* The presence of headaches other than chronic migraine (such as another primary chronic headache or any secondary headache).~* Migraine prophylaxis agents during last 3 months including β-blockers, anti-depressants, calcium channel blockers, anti-epileptic agents or cycle-modulating hormonal drugs.~* Migraine onset after age 50 or the age at onset of CM \> 60 years.~* History of hepatic disorder, nephrolithiasis or other severe illness.~* Cognitive impairment interfering with the subject's ability to follow instructions and describe symptoms.~* Prior fearful experience of acupuncture.~* Bleeding diathesis or anticoagulation.~* Pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- acupuncture (Type: EXPERIMENTAL): None
- topiramate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Apatinib for Inoperable Advanced Chondrosarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1) histologically confirmed high-grade sarcoma;~* 2) initial treatment in the orthopedic oncology departments of the two affiliated hospitals of Peking University;~* 3) tumors not amenable to curative treatment or inclusion in clinical trials;~* 4) unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy;~* 5) measurable lesions according to Response Evaluation Criteria for Solid Tumors (RECIST1.1) ;~* 6) Eastern Cooperative Oncology Group performance status 0 or 1;~* 7) acceptable hematologic, hepatic, and renal function.~Exclusion Criteria:~* had central nervous system metastasis;~* had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia;~* had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on;~* had pleural or peritoneal effusion that needs to be handled by surgical treatment;~* combined with other infections or wounds;~* pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apatinib Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Ages 35-670 in the 14 Linqu villages who received endoscopy examinations in the fall of 1994.~Both men and women will be included.~Patients must sign an informed consent form indicating a willingness to participate in the 42-month trial.~Must be free of debilitating chronic disease.~Must not report allergies to penicillin or similar medications.~Must not have had previous treatment for H. pylori.~Must not have a history of bleeding disorder.~Must not be taking vitamin/mineral supplements on a regular basis.~EXCLUSION CRITERIA:~Persons with cancer (except resected non-melanotic skin cancer), heart failure, emphysema, and other life-threatening illness will be excluded.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Amox/omepr (Type: EXPERIMENTAL): 2 weeks; placebo controlled
- Garlic (Type: EXPERIMENTAL): Supplement for 7 years; placebo controlled
- Vitamins (Type: EXPERIMENTAL): Supplement for 7 years; placebo controlled

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Stable hypertension defined as no new antihypertensive medication started within 6 weeks of Visit 1~* Minimum 6-month history of hypertension and primary glomerular disease~* Hypertensive nephrosclerosis~* Diabetic nephropathy with stable proteinuria as defined by ≥ 1g/24 hours on more than one occasion within 6 months prior to Visit 1~Exclusion Criteria:~* Persistent hypertension~* New anti-hypertensive medications started within 6 weeks of Visit 1~* Significant cardiac disease or Liver disease~* Females of childbearing potential without reliable contraception~* Pregnant women and women who are breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Healthy infants 6-12 or 11-17 weeks of age at the time of dose 1 whose parent/guardian sign a written informed consent and whose parents/guardians can and will comply with the requirements of the protocol.~Exclusion criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine or placebo, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Child is unlikely to remain in the study area during study.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator.~* First or second degree of consanguinity of parents.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 17 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children between 2 to 12 years of age.~2. Children with the diagnosis of asthma having a pram score of more than 4.~3. Children with reactive airways~Exclusion Criteria:~1. Critically ill children who require intubation or mechanical ventilation.~2. Having hypersensitivity or allergy to MgSO4.~3. with history of chronic lung impairment.~4. Whose parents are not giving informed consent for participation in research.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Nebulized Ventolin (Type: ACTIVE_COMPARATOR): Nebulized Ventolin will given to 1st group after every 20 min for 1 hour
- Nebulized Magnesium Sulphate + Ventolin (Type: EXPERIMENTAL): Dose of Nebulized Magnesium sulphate will vary in 3 subgroups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching to Duloxetine From Other Antidepressants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients of at least 18 years of age, who meet criteria for Major Depressive Disorder (MDD)~* Currently non- or only partially-responsive to an SSRI antidepressant after at least 5 weeks of treatment~Exclusion Criteria include:~* Current primary Axis I disorder other than MDD~* Previous diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders~* Patients judged to be at serious suicidal risk.~* Serious medical illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with inoperable pancreatic cancer (ICD-10 C25.0-3) at the Department of Surgical Gastroenterology of Haukeland University Hospital, who have volunteered to participate~Exclusion Criteria:~* Patient participated in an investigational study within 30 days prior to study entry (or, if longer, within five half-lives of the last dose of any investigational drug).~* Patient has severe chronic obstructive pulmonary disease or severe chronic asthma.~* Patient has a history of cardiovascular ischemia, acute myocardial infarction or unstable angina within 3 months prior to study entry.~* Patient has a history of any psychiatric disorder or cognitive impairment that would interfere with participation in the study.~* Patient has a known history of Hepatitis B, Hepatitis C or HIV infection.~* Patient requires dialysis or has severely impaired renal function, defined as a serum creatinine \> 180 mmol/L at the Screening Visit.~* Patient has severe impairment of liver function, defined as a serum albumin level ≤ 25 g/L and/or a Protrombin Time INR \> 2.3 (or APTT \> 6 seconds above the upper limit of normal) at the Screening Visit.~* Patient is pregnant or is breast-feeding.~* Patient is allergic to or intolerant of gemcitabine~* Patient is allergic to or intolerant of SonoVue® BRACCO ultrasound contrast agent~* Any reason why, in the opinion of the investigator, the patient should not participate.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Contrast-enhanced ultrasound (CEUS) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dolutegravir in Real Life in Lesotho

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1-positive~* Initiating or eligible to initiate (offered to initiate) a DTG-based ART regimen~* Informed written consent (and assent, if applicable) provided~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HIV-1-positive individuals (Type: None): HIV-1-positive individuals eligible to receive a DTG-based ART regimen at enrolment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of gastroparesis (e.g., nausea, early satiety, fullness, bloating, upper abdominal pain, retching or vomiting) for at least 3 months prior to Screening~* Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive~* Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score ≥2 and ≤4 at Screening~* Delayed gastric emptying, defined as a gastric emptying half-time (GE t1/2) \> 160 minutes as determined by \[13C\]-octanoate breath test, at Screening~* Upper gastrointestinal (UGI) obstruction ruled out by endoscopy or other imaging reasonably proximal to the diagnosis of gastroparesis~Exclusion Criteria:~* Acute severe gastroenteritis within 2 weeks prior to Screening~* History of gastric outlet obstruction~* Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication~* Recurrent vomiting, defined as vomiting more than 2 days per week~* Hospitalization for treatment of gastroparesis or complications of diabetes within 4 weeks prior to Screening~* Presence of thyroid dysfunction not controlled by treatment. Subjects with abnormal thyroid stimulating hormone (TSH), hypothyroidism, or hyperthyroidism at Screening~* If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level \>10% or a glucose \> 250 mg/dL at Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo
- Sequence 2 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo
- Sequence 3 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo
- Sequence 4 (Type: EXPERIMENTAL): 3-way crossover of velusetrag or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.~* No more than 3 previous anti-myeloma regimens~* No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.~* Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).~Exclusion Criteria:~* Prior development of disease progression during high-dose dexamethasone containing therapy.~* Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm cubed~* Laboratory abnormalities: Platelet count less than 75,000/mm cubed~* Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL~* Laboratory abnormalities: Serum glutamic oxaloacetic transaminase (SGOT, aspartate transaminase \[AST\]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase \[ALT\])greater than 3.0 x upper limit of normal~* Laboratory abnormalities: Serum total bilirubin greater than 2.0 mg/dL~* Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.~* Known hypersensitivity to thalidomide or dexamethasone.~* Development of a desquamating rash while taking thalidomide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-5013/Dex (Type: EXPERIMENTAL): CC-5013 (lenalidomide) plus oral high-dose dexamethasone
- Placebo/Dex (Type: EXPERIMENTAL): Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bupropion Alone or Combined With Nicotine Gum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke 10 or more cigarettes per day~* Motivated to quit~* No physical or mental health issues that would prevent participation~* Not pregnant or willing to prevent pregnancy during treatment~Exclusion Criteria:~* Carbon monoxide (CO) breath test score below 10 parts per million (ppm)~* Center for Epidemiologic Studies Depression Scale (CES-D) score greater than 16~* Heavy alcohol use~* History of eating disorder~* Suicidality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active bupropion-Active gum (Type: ACTIVE_COMPARATOR): 150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
- Active bupropion-Placebo gum (Type: ACTIVE_COMPARATOR): 150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
- Placebo medication-Placebo gum (Type: ACTIVE_COMPARATOR): Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete